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Abstract
Background: Neurological diseases and neuropsychiatric disorders that vary depending on female
life stages suggest that sex hormones may influence the function of neurotransmitter regulatory
machinery such as the dopamine transporter (DAT).
Results: In this study we tested the rapid nongenomic effects of several physiological estrogens
[estradiol (E2), estrone (E1), and estriol (E3)] on dopamine efflux via the DAT in a non-transfected,
NGF-differentiated, rat pheochromocytoma (PC12) cell model that expresses membrane estrogen
receptors (ERs) α, β, and GPR30. We examined kinase, ionic, and physical interaction mechanisms
involved in estrogenic regulation of the DAT function. E2-mediated dopamine efflux is DAT-specific
and not dependent on extracellular Ca2+-mediated exocytotic release from vesicular monoamine
transporter vesicles (VMATs). Using kinase inhibitors we also showed that E2-mediated dopamine
efflux is dependent on protein kinase C and MEK activation, but not on PI3K or protein kinase A.
In plasma membrane there are ligand-independent associations of ERα and ERβ (but not GPR30)
with DAT. Conditions which cause efflux (a 9 min 10-9 M E2 treatment) cause trafficking of ERα
(stimulatory) to the plasma membrane and trafficking of ERβ (inhibitory) away from the plasma
membrane. In contrast, E1 and E3 can inhibit efflux with a nonmonotonic dose pattern, and cause
DAT to leave the plasma membrane.
Conclusion: Such mechanisms explain how gender biases in some DAT-dependent diseases can
occur.
Background
DAT diseases, function, and connection to hormonal states
Parkinson's, Tourette's, attention deficit hyperactivity dis-
order (ADHD), Alzheimer's, and schizophrenia are all
associated with alterations in dopamine-driven function
involving the dopamine transporter (DAT) [1]. The DAT
belongs to a family of Na+/Cl- dependent plasma mem-
brane symporters whose function is to rapidly remove
dopamine from the synaptic space, resulting in the termi-
nation of neurotransmitter signaling. Alterations in the
location and function of the DAT can lead to changes in
dopamine signaling affecting behavioral outcomes and
also increased susceptibility to neuronal insult [2].
Females are more susceptible to the onset or exacerba-
tions of these diseases during life stages when female hor-
monal fluctuations and changes are most pronounced
(adolescence, premenopausal female cycling, perimeno-
pause, and postmenopause), which suggests that changes
in physiological estrogen levels can influence neurochem-
ical pathways including dopamine signaling [3-6]. Many
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studies have linked 17β-estradiol (E2), the predominant
physiological estrogen, to neuroprotective properties, but
the mechanisms of action on the DAT system are not fully
elucidated, and may differ depending upon the levels of
E2 administered and the actions of other estrogens.
Nongenomic effects of E2 on the DAT
Recent attention to the nongenomic actions of E2 can pro-
vide some additional insight as to its effect on the DAT
system. E2 is produced by the ovaries and reaches all tis-
sues by the circulation, but in the brain it is also produced
by conversion of androgens via the enzyme aromatase
which is enriched in mammalian presynaptic boutons [7].
This creates an environment for increased rapid bioavail-
ability of E2 which can elicit nongenomic effects such as
Ca2+ mobilization, kinase activation, and alterations in
dopamine subcellular location via membrane estrogen
receptors (mERs) [8-11]. We have previously examined a
well characterized non-transfected neuronal cell culture
model (PC12 cells) that expresses three known mERs:
mERα, mERβ, and GPR30; in these cells physiological lev-
els of E2 [8,12] and low levels of xenoestrogens [13] can
rapidly reverse actions of the DAT.
Modifications in the phosphorylation state of the DAT by
kinases causes alterations in the function and location of
the DAT [reviewed in [14]]. Amphetamine, a psychostim-
ulant, also causes reversal and altered cellular location of
the DAT which is known to be regulated by kinases, phos-
phatases, and Ca2+  localization and association [15].
Therefore, we hypothesized that the estrogen-mediated
changes in dopamine efflux that we have observed [8,12]
may involve similar mechanisms. In this study we exam-
ined both indirect and direct mechanisms involved in
physiological estrogen-mediated dopamine efflux in con-
junction with the cellular location of the ERs and the DAT.
We studied the involvement of protein kinases A and C
(PKA, PKC), phospho-inositol 3 kinase (PI3K), extracellu-
lar-regulated kinases (ERKs), vesicular release of
dopamine, and changes in intracellular Ca2+ concentra-
tions in the actions of estrogens. Then we addressed the
subcellular localization of ERα, ERβ, the alternative mem-
brane ER (GPR30), and DAT to see if estrogen-induced
trafficking of these proteins in and out of the plasma
membrane could explain some of the regulatory effects on
dopamine efflux. In addition to E2, we also examined the
effects of estrone (E1, at high levels postmenopausally)
and estriol (E3, at high levels during pregnancy) to see if
these estrogens may have some potent nongenomic sign-
aling effects of their own, as we have previously observed
in pituitary cells [16], and if they can also affect DAT func-
tion. These differential regulatory effects on DAT by differ-
ent physiological estrogens may provide some insights
into mechanisms controlling the incidence of neurologi-
cal diseases during life stages accompanied by fluctuations
or change in the steady state levels of these hormones.
Methods
PC12 cell culture
PC12 cells were grown in high-glucose, phenol red-free
RPMI 1640 medium containing 5% fetal bovine serum
(FBS) and 5% equine serum (HS). To promote PC12 dif-
ferentiation and minimize the effects of endogenous hor-
mones respectively, 20 ng/ml NGF-β was added in
medium supplemented with 0.5% of 4× charcoal-stripped
FBS and HS for 48 hrs prior to experiments.
Dopamine efflux assay
We measured 3H-dopamine efflux using selective catecho-
lamine transporter inhibitors to define specific dopamine
transport via the DAT as previously described in [8]. PC12
cells were plated on poly-D-lysine (10 μg/ml)-coated 48-
well plates and uptake buffer (25 mM HEPES, 120 mM
NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1 μM
pargyline, 2 mg/ml glucose) containing 0.2 mg/ml ascor-
bic acid, and desipramine (50 nM), pH 7.4 ± GBR 12909
was added for 60 min at 37°C. In experiments containing
50 nM reserpine, a VMAT inhibitor, a 120 min preincuba-
tion in uptake buffer preceded the 60 min GBR 12909 pre-
incubation. GBR 12909 (100 nM) was added to define
selective efflux by DAT. In experiments containing kinase
inhibitors 10 μM U0126 (a MAPK inhibitor) or 10 μM
Ly294002 (a PI3K inhibitor) were also added during the
60 min uptake buffer addition. 10 μM H89 (a PKA inhib-
itor) and 100 nM Ro32-0432 (a PKC inhibitor) were
added to the uptake buffer for 30 min of preincubation.
For experiments testing Ca2+involvement, 1 μM thapsi-
gargin was added for a 15 min preincubation to empty
intracellular Ca2+ stores, or cells were incubated for 10
min in 0 Ca2+ medium (5 mM EGTA, 10 mM HEPES, 130
mM NaCl, 5.5 mM KCl, 2 mM MgCl2, 7 mM glucose, 30
mM sucrose, pH 7.4) and washed twice in 0 Ca2+ medium.
For all assays cells were loaded with 3H-DA (20 nM) for 10
min prior to two washes in release buffer (25 mM HEPES,
120 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1 μM par-
gyline, 2 mg/ml glucose, 0.2 mg/ml ascorbic acid, and 50
nM desipramine). Release buffer containing treatments,
+/- GBR12909, was then added, and extracellular fluid
was collected at 9 min to assess3H-DA efflux. Triplicate
aliquots were counted in 2 ml Scintiverse II scintillant
using a Beckman LS600SE scintillation counter. Specific
efflux was defined by averaging the disintegrations per
minute due to efflux in the presence of desipramine and
GBR 12909, and then subtracting these values from the
efflux observed with desipramine alone. We subtracted
background (vehicle controls) from treatment groups and
represented the data as 3H-DA efflux compared to % of 9
min 10-9 M E2-induced efflux (set as 100%).
Co-Immunoprecipitation
PC12 cells were collected from five, 150 cm2 Corning tis-
sue culture flasks by scraping, and then centrifuged at
1500 × g, 4°C for 5 min, and resuspended in 2 ml homog-BMC Neuroscience 2009, 10:59 http://www.biomedcentral.com/1471-2202/10/59
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enizing buffer (10 mM Tris-HCl, 1 mM EDTA, 1 mM
EGTA, pH 7.4). Cells were then sonicated 15 times using
a pulse probe sonicator, and further processed using a
Dounce homogenizer, on ice, until the majority of cells
appeared broken by microscopic examination. The result-
ing broken cell preparation was then centrifuged at 1500
× g at 4°C to remove the nuclear pellet. The supernatant
was then centrifuged at 120,000 × g at 4°C to obtain the
plasma membrane pellet, which was then resuspended in
membrane buffer (50 mM Tris-HCl, 1 M NaCl, 5 mM KCl,
2 mM CaCl2, 1 mM MgCl2, 250 mM sucrose, 1 mM EDTA,
1 mM DTT, 1:1000 protease inhibitor cocktail, pH 7.4) by
stirring 8 hours at 4°C and then re-pelleted by centrifuga-
tion for 45 min at 45,000 × g, 4°C. The Bradford Bio-rad
assay was used to determine protein concentration in the
supernatant per manufacturer's instructions. Protein sam-
ples were incubated with 40 μl protein G agarose (Sigma,
P-7700) beads for 10 min at 4°C, then centrifuged using
a microfuge for 1 min. The supernatant was incubated
overnight at 4°C with 2.5 μg DAT antibody (C-20, Santa
Cruz: sc-1433). 50 μl of protein G agarose beads were
washed 3 times in phosphate buffered saline (PBS) and
samples containing antibody were incubated with these
beads for 4 hours at 4°C on a rotator. Beads were then
washed 4 times with PBS for 10 min, each wash. Samples
were eluted using 50 mM glycine buffer pH 2.5, added to
SDS sample buffer and heated at 67°C for 10 min, and
then electrophoresed on a 7.5% acrylamide SDS-PAGE gel
followed by transfer to a nitrocellulose membrane. Blots
were blocked using 2.5% BSA and 2.5% milk in 10 mM
Tris-buffered saline, pH 7.4, for 1 hr before overnight
incubation with primary antibodies (Abs), to ERα
(1:1000 Mc-20, Santa Cruz: sc-542), ERβ (1:2000 Clone
9.88, Sigma: E1276), GPR30 (1:1000 Novus: NLS4271),
and DAT (1:1000, Santa Cruz: sc-33056) at 4°C. Blots
were washed three times for 15 mins with 0.05% TBST
and incubated for 1 hr with peroxidase-conjugated anti-
mouse IgG (Amersham Biosciences) for ERα and ERβ, or
peroxidase-conjugated anti-rabbit IgG (Amersham Bio-
sciences) for GPR30, or peroxidase-conjugated anti-goat
(Amersham Biosciences) for DAT. Immunoreactivity was
detected by enhanced chemiluminescence (Amersham
Biosciences) on Hyperfilm (Amersham) film.
Quantitative plate immuno-assay
Briefly, PC12 cells were plated on poly-D-lysine (10 μg/
ml)-coated 96-well plates at 5000 cells per well, as previ-
ously described [8]. NGF-differentiated, serum-deprived
cells were washed with PBS for 5 min, and treatments
were added in the above uptake buffer with 50 nM
dopamine for 9 min. Cells were fixed for 30 min at room
temperature with 50 μl 2% paraformaldehyde, and 0.2%
gluteraldehyde +/- NP-40 to permeabilize or not permea-
bilize cells, respectively. Cells were then washed twice (5
min each) with PBS and blocked with 0.1% fish gelatin/
PBS for 45 mins at 22°C. Diluted 1° Abs, to ERα (1:1000
Mc-20, Santa Cruz: sc-542), ERβ (1:1500 Clone 9.88,
Sigma: E1276), GPR30 (1:1000 Novus: NLS4271), and
DAT (1:2000 W-17, Sigma: sc-33056) were added over-
night at 4°C; 2 μg anti-clathrin Ab provided a control for
cell permeabilization [8]. Cells were washed three times
in PBS and incubated in appropriate biotinylated 2° Ab
for 1 hr, then washed three times prior to 60 min incuba-
tion with ABC-alkaline phosphatase (AP) solution. Cells
were washed five times with PBS, and the substrate para-
nitro-phenol phosphate (pNpp) plus 0.5 mM levamisole
was added in 100 mM sodium bicarbonate solution for 30
mins at 37°C. Plates were read at A405 nm and then rinsed
and stained with 0.1% crystal violet for 30 mins at room
temperature, then washed with ddH20 and dried over-
night. Dye was then extracted from each well with 50 μl
10% acetic acid, read at A590, and used to estimate cell
number per well. Data are plotted as % of vehicle-treated
control levels (A405 nm/A590 nm).
Statistics
Statistical analyses for all assays were performed using Sig-
maStat software (Chicago, IL, USA), and statistical signif-
icance was accepted at p < 0.05. Figure legends contain the
n for each experimental set and the specific statistical anal-
ysis applied. All experiments were repeated 3 times.
Results
PKC and MAPK are involved in E2-mediated dopamine 
efflux
We have previously demonstrated that a 9 min 10-9 M E2
treatment causes DAT specific dopamine efflux in non-
transfected NGF-differentiated PC12 cells expressing ERα,
ERβ, and GPR30 [8]. This led us to use this model to first
explore the possible control of E2-mediated dopamine
efflux by the most often reported mechanism, kinase
involvement. Many kinases including PI3K, PKA,
mitogen-activated protein kinases (MAPKs), and PKC are
known to regulate DAT activity, specifically ampheta-
mine-induced dopamine efflux, and DAT location [17-
20]. We pre-incubated PC12 cells with inhibitors for PKC,
MAPK/ERK kinases (MEK), PKA, or PI3K, using optimal
preincubation times for each inhibitor (see materials and
methods), and then added 10-9 M E2 for 9 mins prior to
measuring dopamine efflux. Figure 1 shows that inhibit-
ing either MEK or PKC significantly inhibited E2-mediated
dopamine efflux. Inhibiting PI3K or PKA did not affect E2-
mediated dopamine efflux.
The presence of intracellular Ca2+ is required for E2-
mediated dopamine efflux
Although we have controlled for dopamine flux specifi-
cally through the DAT through the use of DAT- and nore-
pinephrine-selective transporter inhibitors, the addition
of these inhibitors does not account for the possibility ofBMC Neuroscience 2009, 10:59 http://www.biomedcentral.com/1471-2202/10/59
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exocytotic release of dopamine which is dependent on
extracellular Ca2+. Intracellular Ca2+ is also an important
second messenger signal that is required to activate Ca2+-
dependent PKC isoforms. Compared to 9 min 10-9 M E2
treatment (Figure 2), preincubating the cells for 10 min in
0 Ca2+ medium containing 5 mM EGTA did not inhibit E2-
induced dopamine efflux, but instead actually increased
dopamine efflux. However, the prior emptying of intracel-
lular stores of Ca2+ with thapsigargin did reverse E2-medi-
ated dopamine efflux.
Vesicular release of dopamine is not involved in E2-
mediated dopamine efflux
We then further examined the mechanisms involved in
the E2-induced movement of dopamine to the outside of
PC12 cells. To confirm that vesicular release of dopamine
is not involved in E2-mediated dopamine efflux mecha-
nism, we preincubated our cells with reserpine, a vesicular
monoamine transporter (VMAT) inhibitor which causes
emptying of dopamine from VMATs. Figure 3 shows that
the inhibition of vesicular release does not inhibit subse-
quent E2-induced dopamine efflux (and that the inhibitor
alone does not cause dopamine efflux), further confirm-
ing that the E2-mediated dopamine efflux that we have
observed is specifically via the DAT. We found that the
dopamine efflux resulting from treatment with reserpine
alone compared to the control (in the absence of E2) are
similar (within the same error around zero) indicating
that basal and reserpine control are not different from one
another. We also noted that inhibiting VMATs signifi-
cantly increased E2-mediated dopamine efflux.
Effects of three physiological estrogens on dopamine 
efflux and trafficking of the DAT and ERs
Changes in DAT membrane presence and functioning
could be an important mechanism for alterations in neu-
rochemical signaling by several physiological estrogens
3H-DA efflux assay after a 9 min 10-9 M E2 treatment in the  presence of kinase inhibitors Figure 1
3H-DA efflux assay after a 9 min 10-9 M E2 treatment 
in the presence of kinase inhibitors. A) U0126 is a MEK 
inhibitor, LY294002 is a PI3K inhibitor, H89 is a PKA inhibi-
tor, and Ro 32-0432 is a PKC inhibitor. The Y-axis is % of 10-
9 M E2dopamine efflux response at 9 mins, dashed lines are 
errors around the mean. * = p < 0.05 significance compared 
to control, # = p < 0.05 from E2 treatment, n = 24 in 3 
experiments.
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3H-DA efflux assay after a 9 min 10-9 M E2 treatment in the  presence of Ca2+ depleted medium compared to normal  efflux medium Figure 2
3H-DA efflux assay after a 9 min 10-9 M E2 treatment 
in the presence of Ca2+ depleted medium compared 
to normal efflux medium. A 15 minute pretreatment with 
thapsigargin releases intracellular Ca2+ stores; 0 Ca2+ media 
removes extracellular Ca2+ from the treatment. The Y-axis is 
% of 10-9 M E2 dopamine efflux response at 9 mins, dashed 
lines are errors around the mean. * = p < 0.05 significance 
compared to control, # = p < 0.05 vs. thapsigargin, ^ = p < 
0.05 vs. normal efflux medium, n = 24 in 3 experiments.
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3H-DA efflux assay after 9 min 10-9 M E2 treatment in the  presence of VMAT inhibitor Figure 3
3H-DA efflux assay after 9 min 10-9 M E2 treatment in 
the presence of VMAT inhibitor. PC 12 cells were pre-
treated for 2 hrs with reserpine, a VMAT inhibitor, in order 
to inhibit vesicular release of DA, and then treated with 10-9 
M E2 or ethanol (vehicle control). The Y-axis is % of 10-9 M E2 
dopamine efflux response at 9 mins, dashed lines are errors 
around the mean. * = p < 0.05 significance compared to con-
trol, # = p < 0.05 vs. E2 treatment without reserpine. n = 18 
in 3 experiments.
-100
0
100
200
D
o
p
a
m
i
n
e
 
E
f
f
l
u
x
,
 
%
 
o
f
 
E
2
Reserpine
*
#
#
Reserpine + E2BMC Neuroscience 2009, 10:59 http://www.biomedcentral.com/1471-2202/10/59
Page 5 of 9
(page number not for citation purposes)
(not just E2). Therefore, we first monitored the concentra-
tion-dependent effects of a 9 min physiological estrogen
(E2, E1, or E3) treatment on dopamine efflux (Figure 4). E2
(Figure 4A), caused dopamine efflux at 10-14 M followed
by a return to baseline, and then another peak of
dopamine efflux at the higher concentrations (100 pM-10
nM). E1 (Figure 4B) and E3 (Figure 4C), did not cause
dopamine efflux at the tested concentrations at 9 min but
at 10-13 and 10-10 M E1 significantly inhibited dopamine
efflux. E3 (Figure 4C) also did not cause dopamine efflux,
but did cause inhibition at 10-15, and 10-9 M concentra-
tions with no effect at other concentrations. These bimo-
dal concentration effects of estrogens on dopamine efflux
are typical of nongenomic actions that we have described
before on these and other cell types [8,21,22]. Such
changes in dopamine efflux could be due to effects of
estrogens on the trafficking of the DAT, and mERs (that
are likely to regulate the DAT) to or from the plasma
membrane, which we then investigated, shown in Figure
5. We selected the 10-9 M concentration of each estrogen
treatment at 9 min to investigate these possible effects
(shown by arrows in Fig 4) because this is a physiological
level for each [23], and because they cause distinctively
different effects on efflux by the different hormones. E2 at
this concentration, which had caused increases in efflux,
increased the amount of ERα and decreased the amount
of ERβ in the plasma membrane (Figure 5A). DAT mem-
brane levels were unchanged. E1 treatment caused traffick-
ing of all three ERs and the DAT away from the plasma
membrane (Figure 5B) perhaps removing them from their
place of association and functional influence. E3 treat-
ment which caused inhibition of efflux did cause removal
of plasma membrane DAT, but trafficking of the ERs was
not affected (Figure 5C).
The DAT directly associates with ERα and ERβ in the 
plasma membrane
We have previously reported that ERα is the predominant
receptor mediator of E2 effects on dopamine efflux [8].
Therefore, we next tested for the direct interaction
between the DAT and ER proteins in the plasma mem-
brane at a time (9 mins) and concentration (10-9 M) of
optimal hormone-mediated dopamine efflux (Figure 6).
In vehicle-treated (EtOH) control samples the pull-down
pattern suggests a ligand-independent association of ERα
and ERβ with the DAT. That is, plasma membrane-
enriched fractions immunoprecipitated with a DAT anti-
body, co-immunoprecipitated ERα and ERβ, but not
GPR30. We also tested for the presence of each ER and the
DAT in plasma membrane total fractions and showed that
each protein of interest was present (total). After E2 treat-
ment ERα and ERβ are still present in the DAT pull-down,
and GPR30 remains absent. A slight reduction in the
amount of ERα is seen after E2 treatment. Therefore, prior
to and immediately following E2 treatment, ERα and ERβ
Concentration-dependent dopamine efflux patterns for E2,  E1, and E3 at 9 min (A) E2 (B) E1 (C) E3 Figure 4
Concentration-dependent dopamine efflux patterns 
for E2, E1, and E3 at 9 min (A) E2 (B) E1 (C) E3. Arrows 
indicate the concentration chosen for quantitative plate assay 
(Fig 5) ERα, ERβ, and GRP30 levels after 9 min 10-9 M E2 
treatment were previously reported in [8] * = p < 0.05 from 
control, # = p < 0.05 from membrane, and are shown here 
for comparison to changes caused by E1 and E3. n = 24 in 3 
experiments
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are associated with the DAT, which indicates a potential
for a significant level of control between estrogens and the
DAT.
Discussion
Our studies pinpoint the contributions of regulatory
kinase cascades and specific sources of regulatory Ca2+
ions in the mechanisms of estrogenic control of the DAT.
In addition, we demonstrate a role for other physiological
estrogens besides E2 in regulating the function/subcellular
localization of the DAT, and a physical association of two
ERs (α and β) with the DAT before and during estrogen
action. Such findings lay the basis for understanding how
estrogen profiles associated with different life stages of
women may influence processes and diseases associated
with DAT function.
Previous in vivo studies have reported conflicting results
on the hormonal regulation of DAT expression. One find-
Quantitative plate assay measuring immunoreactive protein  levels for plasma membrane and total ERα, ERβ, GPR30, and  DAT after 9 min E2, E1, and E3 treatment Figure 5
Quantitative plate assay measuring immunoreactive 
protein levels for plasma membrane and total ERα, 
ERβ, GPR30, and DAT after 9 min E2, E1, and E3 
treatment. (A) E2 (B) E1 (C) E3. ERα, ERβ, and GRP30 levels 
after 9 min 10-9 M E2 treatment were previously reported in 
[8] * = p < 0.05 from vehicle control, # = p < 0.05 from 
membrane, and are shown here for comparison to changes 
caused by E1 and E3. n = 24 in 3 experiments
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Direct association of dopamine transporter and 
estrogen receptors on the plasma membrane vs. in 
total protein. Co-immunoprecipitation of dopamine trans-
porter after 9 min 10-9 M E2 treatment and subsequent prob-
ing with antibodies for DAT, ERα, ERβ, and GPR30. This is a 
representative immunoblot of 3 experiments
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ing reports that E2 up-regulates DAT while others have
shown that E2 down-regulates DAT expression [24,25].
Although, alteration in DAT expression leads to modifica-
tions in the capacity for a neuron to transport dopamine
causing a decrease or increase in neurotransmitter signal-
ing, we are reporting for the first time the nongenomic
and acute mechanisms by which estrogens can regulate
the DAT function.
Our data indicate that E2-mediated dopamine efflux is car-
rier-mediated transport based on our finding that it is
dependent upon endogenous Ca2+, and that inhibition of
exocytotic release does not inhibit hormone stimulated
dopamine efflux. When inhibiting VMAT storage vesicles
we observed an increase in E2-mediated dopamine efflux.
Exocytotic release of dopamine via VMAT trafficking is
dependent upon exogenous Ca2+, but reserpine, a VMAT
inhibitor, causes emptying of dopamine from VMATs
leading to increased levels of intracellular dopamine. We
hypothesize that our observed level of increased efflux
could be due to an increase in the concentration gradient
of intracellular dopamine, thus facilitating dopamine
efflux. Previous studies have shown that Ca2+-free
medium does not alter baseline DAT uptake properties
[26], further supporting our conclusion that this estro-
genic effect is on transporter-mediated dopamine efflux.
However, the removal of extracellular Ca2+ caused a signif-
icant increase in E2-induced dopamine efflux which sug-
gests extracellular Ca2+  sensitive kinase activation or
phosphatase activity might play a role in regulating E2-
mediated dopamine efflux. Calcium/calmodulin depend-
ent kinase II (CaMKII) activity and association with the
DAT is known to be important for syntaxin 1A association
with DAT and AMPH-mediated dopamine efflux [27].
Syntaxin 1A can regulate ion channels and neurotransmit-
ter transporters [28], so the removal of extracellular Ca2+
could disrupt CaMKII and syntaxin 1A association and
thus affect estrogen-mediated efflux at this level. Future
studies will further explore the mechanistic relationship
between E2-mediated dopamine efflux and CaMKII and
how this mechanism may resemble AMPH-mediated
dopamine efflux.
Using inhibitors for a series of kinases, we found that both
PKC and MEK are important for E2-mediated dopamine
efflux. The DAT contains many PKC consensus sites and
PKC activity is also important for the interaction of many
of the DAT-associated proteins that control its location
and activity. AMPH-mediated dopamine efflux is depend-
ent primarily on a Ca2+ sensitive PKC isoform, PKCβ [17].
Because E2 and AMPH both require intracellular Ca2+ and
PKC activity, it could be an interesting common point of
regulation suggesting similar mechanisms of control.
MEK and its downstream kinases are known to be one
aspect of controlling trafficking of the DAT to and from
the plasma membrane. In our experiments E2 did not
change the subcellular location of the DAT, though the
other tested estrogens did at the nM concentrations tested.
Most likely our effects of E2-mediated dopamine efflux
were mediated by a PKC-dependent mechanism. It is also
possible that MEK cascade activation is secondary via
dopamine signaling. D2 receptor activation by dopamine
leads to MAPKs activation and increased intracellular
Ca2+, which in turn also activates PKC [29]. We have pre-
viously reported that E2 also activates ERK in other cell sys-
tems [9,11].
We previously reported that E2 causes rapid dopamine
efflux via mER activation, specifically by ERα liganding,
with inhibitory regulation from ERβ and GPR30, accom-
panied by no change in plasma membrane levels of the
DAT [8]. Regulation that removes DAT from the plasma
membrane could alter both dopamine uptake and efflux,
which in turn could lead to prolonged signaling changes
due to altered synaptic dopamine levels. Other studies
have shown that an increase in the presence of membrane
DAT levels is an indicator of increased susceptibility to
neurotoxins that are transported by the DAT; this creates
an environment for increased uptake of synaptic
dopamine which if not sequestered in VMATs, could
increase intracellular reactive oxygen species (ROS) levels.
E1, which is increased following menopause, does not
cause dopamine efflux at the tested physiological concen-
trations in our studies, but does cause trafficking of the
DAT and all three ERs (ERα, ERβ, and GPR30) from the
plasma membrane. E3, a hormone which is high during
pregnancy did not cause dopamine efflux, but at a physi-
ological concentration significantly inhibited dopamine
efflux while allowing retention of all three ERs at the
plasma membrane. Since DAT plasma membrane levels
controlling function determine the level of available syn-
aptic dopamine, and E1 and E3 both cause removal of
membrane DAT and inhibition of dopamine efflux, we
speculate that this could account for some mood altera-
tions during times of these hormonal fluctuations. E3 not
only removes DAT from the membrane but reduces the
total cellular DAT content. Because E2 and E1 treatment
changed the subcellular location of the ERs to varying
degrees, it is possible that these protein movements could
alter or destabilize associations with the DAT which we
will test in future studies.
We observed ligand-independent association of ERα and
ERβ (but not GPR30) and DAT in vehicle-treated samples,
while a 10-9 M E2 treatment decreased (but did not elimi-
nate) association between ERα and the DAT. Both the
DAT and ERs are reported to be located within caveolin-
containing lipid rafts in the plasma membrane, so these
associations are not surprising. Our co-IP studies were
designed to monitor if there is an association between theBMC Neuroscience 2009, 10:59 http://www.biomedcentral.com/1471-2202/10/59
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ERs and the DAT, but in order to determine if or how E2
treatment quantitatively caused changes in this associa-
tion, further approaches are needed.
Conflicting studies have reported both increases and
decreases in DAT levels in ADHD patients which indicate
that other factors are involved. Stimulants that block DAT
function are used in treatment regiments for ADHD
resulting in improved inattention measurements [29].
During the follicular phase of the menstrual cycle females
are more responsive to stimulants such as amphetamine,
which suggests that the effects of estrogens and stimulants
that target DAT interact [30-32].
Conclusion
The significance of estrogen-coupled regulation of the
DAT by both direct and indirect (kinase-mediated) inter-
actions between ERs and the DAT should provide insights
into how neurological diseases which involve the DAT are
related to developmental, gender, and life stage issues.
Now that we are beginning to mechanistically explore this
system using well defined cell models, we will be able to
ask more specific questions in in vivo systems relating to
disease states. Such regulation may suggest new ideas
about treatment and prevention of diseases associated
with extreme hormonal fluctuations such as in postpar-
tum depression.
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